JUBLPHARMA.BOJUBLPHARMA.BOBSE
Loading
Operating Income PerformanceStable
Percentile Rank50
3Y CAGR-2.8%
5Y CAGR-2.1%
Year-over-Year Change
Profit from core business operations before interest and taxes
3Y CAGR
-2.8%/yr
vs -3.9%/yr prior
5Y CAGR
-2.1%/yr
Consistent
Acceleration
+1.1pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive growthStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $23.56B | +14.1% |
| 2024 | $20.64B | +4.0% |
| 2023 | $19.85B | -22.7% |
| 2022 | $25.68B | -1.9% |
| 2021 | $26.19B | +0.0% |
| 2020 | $26.18B | -26.5% |
| 2019 | $35.59B | +18.2% |
| 2018 | $30.12B | +16.6% |
| 2017 | $25.83B | +4.8% |
| 2016 | $24.64B | - |